Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

75 Results

Unlock all the news: Be the first to know and act before the market!
100% Free Registration
European Midday Briefing : Stocks Gain as Bonds Track Treasuries Lower
DJ
Lonza Taps Siegfried Holding's Wolfgang Wienand as Next CEO
DJ
Lonza chairman to step down, drugmaker confirms targets, shares soar
RE
Manufacturer Lonza says it will not fill obesity drug syringes
RE
Lonza Shares Drop After Warning of 2024 Profitability Shortfall
DJ
Lonza cuts 2024 margin target again after CEO departure
RE
LONZA GROUP : A sudden departure
Alphavalue
European Midday Briefing : Cautious Start to Week Packed with Policy Decisions
DJ
European shares ease, with central banks in focus; Lonza drops on CEO exit
RE
Lonza Shares Tumble After News of CEO Departure
DJ
Lonza CEO Pierre-Alain Ruffieux to Leave
DJ
Lonza CEO to leave by mutual agreement
RE
Board Announcement
EQ
Lonza Group AG Announces CEO Changes
CI
Transcript : Lonza Group AG, H1 2023 Earnings Call, Jul 21, 2023
Lonza : Half-Year 2023 Results Report
PU
Lonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin
EQ
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes Cell Therapies
AQ
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
BU
Transcript : Lonza Group AG, Q1 2023 Earnings Call, May 10, 2023
Q1 2023 Qualitative Update: Business Performance In Line With  Full-Year Trajectory
EQ
Lonza Group Seeks Mergers and Acquisitions
CI
Transcript : Lonza Group AG, 2022 Earnings Call, Jan 25, 2023
Lonza underscores growth prospects with share buy-back, dividend hike
RE
Lonza : Full-Year 2022 Results Report
PU
Lonza Delivers Strong 2022 Performance with 15.1% CER Sales Growth and 32.1% CORE EBITDA Margin
EQ
Transcript : Lonza Group AG Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 10:30 AM
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
EQ
Transcript : Lonza Group AG, H1 2022 Earnings Call, Jul 22, 2022
Lonza Confident on 2022 Goals as 1st Half Sales Book Healthy Rise
DJ
Lonza : Half-Year Results Report
PU
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
EQ
Maria Soler Nunez appointed as Head, Group Operations
EQ
Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH)
EQ
Lonza and Kodiak open custom-built bioconjugation facility
AQ
Grand Opening of Kodiak Sciences Purpose-Built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases
AQ
Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases
PR
Lonza Group - Christian Seufert appointed as President of Capsules and Health Ingredients Division
AQ
Lonza : Christian Seufert appointed as President of Capsules and Health Ingredients Division
PU
Lonza : is among the 2022 World's Most Ethical Companies, as recognized by Ethisphere
PU
Transcript : Lonza Group Ltd, Q4 2021 Earnings Call, Jan 26, 2022
Lonza : Full-Year Results Report
PU
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
EQ
Transcript : Lonza Group Ltd - Analyst/Investor Day
Lonza : Philippe Deecke appointed as Chief Financial Officer of Lonza Group
PU
Transcript : Lonza Group Ltd, H1 2021 Earnings Call, Jul 23, 2021
Vaccine business helps Lonza lift 2021 sales outlook
RE
Lonza : Vaccine business helps Lonza lift 2021 sales outlook
RE
Lonza : Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
PU
Lonza : Announces Expansion Plans for Next-Generation Mammalian Manufacturing Facilities in Visp (CH) and Portsmouth (US)
PU
No results for this search
  1. Stock Market
  2. Advanced search
  3. Pierre-Alain Ruffieux
  4. News